The deal is to sell one of the two business undertakings of ZAHL for a lump sum consideration of Rs. 2921 crores on a cash free and debt free basis,
Jubilant successfully challenged Bracco's patent infringement claims in an Inter Parties Review (IPR) proceeding before the U.S. Patent Office
The facility is expected to be completed in 2024
In some countries such as France, Italy, Spain and the Balkan region, Menarini Group will lead the commercialisation effort, as part of an exclusive licensing agreement signed with Glenmark
_256_384.jpeg)
Against the present demand from 20 states of 6,785 MT/day of Liquid Medical Oxygen, the Government of India has from 21st April allocated 6,822 MT/day to these states
Lonza's Ibex Design end-to-end offering will cover the development stages of IMT-009 from development candidates through early clinical studies
Lonza Specialty Ingredients has become LifeClean’s first strategic industrial partner.
Intrarosa will not only expand and strengthen our product portfolio into Women's Health in Canada but will cater to satisfy the unmet medical needs.
Vivimed strategy is to increase its share of Branded products in CIS Markets.
The next phase of growth in pharma depends on the industry-oriented workforce, risk investment, academic revamp, and creation of R&D hubs, say experts .
Subscribe To Our Newsletter & Stay Updated
